
Researchers report the ability to improve safety and efficacy using a CRISPR-Cas9 variant known as miCas9.
Using a new variant to repair DNA will improve both safety and effectiveness of the much-touted CRISPR-Cas9 tool in genetic research, Michigan Medicine researchers say.
Those two key problems – safety and efficacy – are what continue to hold CRISPR-Cas9 gene targeting back from its full clinical potential, explains co-senior author Y. Eugene Chen, M.D., Ph.D., a professor of internal medicine, cardiac surgery, physiology, pharmacology and medicinal chemistry, from the Michigan Medicine Frankel Cardiovascular Center.
The new CRISPR-Cas9 variant improves efficiency when inserting a gene or DNA fragment to a precise location in the genome, known as knocking in. It also reduces the rate of unintended insertions or deletions, known as indels, of base pairs that often happen while gene editing.
“We name it meticulous integration Cas9, or miCas9, to reflect its extraordinary capacity to enable maximum integration, yet with minimal indels, as well as to recognize its development at the University of Michigan,” write senior authors Chen, Jifeng Zhang and Jie Xu for Nature’s “Behind the Paper” series. “It provides a ‘one small stone for three birds’ tool in gene editing.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
MiCas9
- Feed has no items.
Go deeper with Google Headlines on:
MiCas9
[google_news title=”” keyword=”miCas9″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
CRISPR-Cas9
- Genetic Welding: Unleashing Evolution’s Future or Playing With Ethical Fire?
With CRISPR-Cas9 technology, humans can now rapidly change the evolutionary course of animals or plants by inserting genes that can easily spread through entire populations. Evolutionary geneticist ...
- Expert calls for human-controlled evolution to be named 'genetic welding'
Humans are changing evolutionary trajectories via CRISPR tech. Perhaps now is the time to pause and think about what this all actually means.
- Vertex (VRTX) Inks Licensing Deal With CRISPR for Diabetes Drug
Vertex Therapeutics (VRTX) enters into a licensing agreement with CRISPR for the latter's gene-editing technology to accelerate the development of its type I diabetes hypoimmune therapy programs.
- Vertex to pay CRISPR $100m to use gene editing tech for diabetes therapy
Vertex will pay CRISPR Therapeutics $100m up-front for non-exclusive rights to its technology with the goal of developing a certain type of therapy for diabetes.
- Bullish News May Push Vertex Pharmaceuticals Above 52-Week High
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) is positioned to make a new run at the 52-week high of $325.19 as the stock is confirming a cup base pattern. The biotechnology company’s stock is up 7.3% ...
Go deeper with Google Headlines on:
CRISPR-Cas9
[google_news title=”” keyword=”CRISPR-Cas9″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]